101. A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.
- Author
-
Davies DJ, Crowe M, Lucas N, Quinn J, Miller DD, Pritchard S, Grose D, Bettini E, Calcinaghi N, Virginio C, Abberley L, Goldsmith P, Michel AD, Chessell IP, Kew JN, Miller ND, and Gunthorpe MJ
- Subjects
- Analgesics pharmacology, Antidepressive Agents pharmacology, Benzimidazoles pharmacology, Drug Discovery, High-Throughput Screening Assays, Humans, Patch-Clamp Techniques, Radioligand Assay, Receptors, N-Methyl-D-Aspartate metabolism, Structure-Activity Relationship, Analgesics chemical synthesis, Antidepressive Agents chemical synthesis, Benzimidazoles chemical synthesis, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors
- Abstract
A series of novel benzimidazoles are discussed as NR2B-selective N-methyl-d-aspartate (NMDA) receptor antagonists. High throughput screening (HTS) efforts identified a number of potent and selective NR2B antagonists such as 1. Exploration of the substituents around the core of this template identified a number of compounds with high potency for NR2B (pIC(50) >7) and good selectivity against the NR2A subunit (pIC(50) <4.3) as defined by FLIPR-Ca(2+) and radioligand binding studies. These agents offer potential for the development of therapeutics for a range of nervous system disorders including chronic pain, neurodegeneration, migraine and major depression., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF